Cocrystal Pharma, Inc. to Post Q3 2024 Earnings of ($0.59) Per Share, Zacks Small Cap Forecasts (NASDAQ:COCP)

Cocrystal Pharma, Inc. (NASDAQ:COCP) – Equities research analysts at Zacks Small Cap issued their Q3 2024 earnings estimates for shares of Cocrystal Pharma in a research report issued on Tuesday, April 23rd. Zacks Small Cap analyst D. Bautz forecasts that the company will earn ($0.59) per share for the quarter. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($2.18) per share. Zacks Small Cap also issued estimates for Cocrystal Pharma’s FY2026 earnings at ($2.58) EPS.

Cocrystal Pharma (NASDAQ:COCP) last announced its earnings results on Thursday, March 28th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.13.

Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Cocrystal Pharma in a research report on Thursday, April 4th.

Cocrystal Pharma Stock Performance

Shares of NASDAQ:COCP opened at $1.50 on Thursday. The company’s 50 day moving average price is $1.49 and its two-hundred day moving average price is $1.63. Cocrystal Pharma has a 12-month low of $1.33 and a 12-month high of $3.29.

About Cocrystal Pharma

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.